

Acylated flavonol glycosides from *Delphinium staphisagria*

Jesús G. Díaz^a, Armando J. Carmona^a, Pedro Perez de Paz^b, Werner Herz^{c,*}

^aInstituto Universitario de Bio-Orgánica “Antonio González”, La Laguna, Tenerife, Spain

^bDepartamento de Botánica, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain

^cDepartment of Chemistry and Biochemistry, The Florida State University, Tallahassee, FL 32306-4390, United States

Received 16 April 2008; received in revised form 12 June 2008; accepted 16 June 2008

Available online 7 July 2008

Abstract

An ethanolic extract of the aerial parts of *Delphinium staphisagria* L. from Tenerife yielded four new flavonol glycosides 2''-acetylastragalín, 2''-acetylpaeonoside, quercetin 3-*O*-(2-acetyl- β -glucopyranoside)-7-*O*- β -glucopyranoside and 2''-acetylpetiolaroside in addition to astragalín, isoquercitrín, paeonoside, kaempferol 3-*O*- β -glucopyranoside-7-*O*- α -rhamnopyranoside, petiolaroside and rutin.

© 2008 Phytochemical Society of Europe. Published by Elsevier B.V. All rights reserved.

Keywords: *Delphinium staphisagria*; Ranunculaceae; Flavonol glycosides; 2''-Acetylastragalín; 2''-Acetylpaeonoside; Quercetin 3-*O*-(2-acetyl- β -glucopyranoside)-7-*O*-2''-acetylpetiolaroside

1. Introduction

The literature contains numerous publications on the diterpenoid alkaloids of *Delphinium* species but articles on *Delphinium* flavonoids are relatively rare (Arazashvili et al., 1973, 1974; Strzelecka and Dobrowolska, 1976; Lomadze et al., 1976; Yunusova and Nigmanova, 1976; Warnock et al., 1983; Özden et al., 1998; Yoshimitsu et al., 2007). Several years ago one of us, with others, reported new diterpene alkaloids from the aerial parts of *Delphinium staphisagria* L. (Díaz et al., 2000). The present article deals with flavonols in the extracts of the aerial parts of this species. Isolated were the kaempferol-based glycosides astragalín (**1**), 2''-acetylastragalín (**1a**), paeonoside (**3**), 2''-acetylpaeonoside (**3a**), kaempferol β -glucopyranoside-7-*O*-rhamnopyranoside (**5**) and the quercetin-based glycosides isoquercitrín (**2**) contaminated with rutin (**7**), quercetin 3-(2-acetyl- β -glucopyranoside)-7-*O*- β -glucopyranoside (**4**), petiolaroside (**6**) and 2''-acetylpetiolaroside (**6a**). Flavonol glucosides **1a**, **3a**, **4** and **6a** are new naturally occurring flavonoids and have not been described previously.

2. Results and discussion

The *n*-BuOH soluble fraction of the EtOH–H₂O (4:1) extract of the aerial parts of *D. staphisagria* was submitted to multiple

chromatographic steps to afford the known flavonoids astragalín (**1**), isoquercitrín (**2**) contaminated with rutin, paeonoside (**3**), kaempferol 3-*O*- β -glucopyranoside-7-*O*- α -rhamnopyranoside (**5**, Özden et al., 1998), petiolaroside (**6**) and the new flavonol glycosides 2''-acetylastragalín (**1a**), 2''-acetylpaeonoside (**3a**), quercetin 3-*O*-(2-acetyl- β -glucopyranoside)-7-*O*- β -glucopyranoside (**4**) and 2''-acetylpetiolaroside (**6a**). Known flavonoids **1–3**, **5** and **6** were identified by HRMS, ¹H and ¹³C NMR spectrometry and conversion to the known respective peracetates.


In the case of new compound **1a** location of the acetate function on C-2'' of the glucose moiety was deduced by comparing the ¹H and ¹³C NMR spectra (see Section 3) with those of astragalín (**1**), the significant difference being the downfield shift of the H-2'' signal from δ 4.32 (in pyridine-*d*₅) for **1** to δ 5.89 for **1a**. In the ¹³C NMR spectrum acetylation at C-2'' was evidenced by the upfield shifts of C-1'' and C-3'' from δ 104.5 resp. 79.0 in **1** to δ 101.2 resp. 76.3 in **1a**. To verify the structure further acetylation of monoacetate **1a** produced the known astragalín heptaacetate (**1d**) as well as two new isomeric astragalín hexaacetates **1b** and **1c** whose ¹H and ¹³C NMR spectra (see Section 3) when compared with those of **1a** and **1d** indicated that **1b** was the 7,4',2'',3'',4'',6''-hexaacetate of astragalín, i.e. kaempferol 3-*O*- β -glucopyranoside 7,4',2'',3'',4'',6''-hexaacetate, and that **1c** was the isomeric kaempferol 3-*O*- β -glucopyranoside 5,4',2'',3'',4'',6''-hexaacetate.

In a quite similar fashion comparison of the ¹H and ¹³C NMR spectra of new monoacetate **3a** with those of paeonoside

* Corresponding author. Tel.: +1 850 644 2774; fax: +1 850 644 8281.

E-mail addresses: jdulin@chem.fsu.edu, herz@chem.fsu.edu (W. Herz).

(3), also a constituent of the extract, showed that the new acetoxy group esterified C-2'' of the glucoside on C-3 of the flavonol skeleton, the signal of the corresponding proton having shifted from δ 4.36 in **3** to δ 5.88 in **3a**, a change mirrored in the upfield shift of the C-1'' and C-3'' signals from δ 103.9 resp. 79.0 in **3** to δ 101.0 resp. 76.4 in **3a**, while peracetylation of **3a** produced paeonoside decaacetate (**3b**) identical with material prepared from paeonoside. Similarly in the ^1H and ^{13}C NMR spectra of new monoacetate **6a** the signal of H-2'' was shifted downfield from δ 4.34 m in petiolaroside (**6**) to δ 5.87 dd and the C-1'' and C-3'' signals were shifted from δ 104.7 resp. 79.0 in **6** to δ 101.5 resp. 76.5, all indicating acetylation at C-2'', while peracetylation of **6a** produced petiolaroside undecaacetate (**6b**) identical with material prepared from petiolaroside itself. Finally, in the ^1H and ^{13}C NMR spectra of new monoacetate **4** the H-2'' signal occurred at δ 5.85 dd with the C-1'' and C-3'' signals being found at δ 102.1 resp. 75.2, all indicating location of the acetate on C-2'', while peracetylation of **4** yielded the known quercetin 3,7-diglucoside undecaacetate (**4a**).



- (1) astragalol: $R_1 = \text{Glc}$, $R_2 = R_3 = R_4 = R_5 = \text{H}$
 (1a) 2'' acetylastragalol: $R_1 = \text{Glc}$ 2''-Ac; $R_2 = R_3 = R_4 = R_5 = \text{H}$
 (1b) $R_1 = \text{Glc-Ac}$; $R_2 = R_4 = \text{H}$, $R_3 = R_5 = \text{Ac}$
 (1c) $R_1 = \text{Glc-Ac}$; $R_2 = R_5 = \text{Ac}$, $R_3 = R_4 = \text{H}$
 (1d) astragalol heptaacetate: $R_1 = \text{Glc-Ac}$; $R_2 = R_3 = R_5 = \text{Ac}$, $R_4 = \text{H}$
 (2) isoquercitrin: $R_1 = \text{Glc}$; $R_2 = R_3 = R_5 = \text{H}$, $R_4 = \text{OH}$
 (2a) isoquercitrin octaacetate: $R_1 = \text{Glc-Ac}$; $R_2 = R_3 = R_5 = \text{Ac}$, $R_4 = \text{OAc}$
 (3) paeonoside: $R_1 = R_3 = \text{Glc}$; $R_2 = R_4 = R_5 = \text{H}$
 (3a) 2''-acetylpaenoside: $R_1 = \text{Glc}$ 2''-Ac; $R_3 = \text{Glc}$, $R_2 = R_4 = R_5 = \text{H}$
 (3b) paeonoside decaacetate: $R_1 = R_3 = \text{Glc-Ac}$; $R_2 = R_5 = \text{Ac}$, $R_4 = \text{H}$
 (4) quercetin 3-O-(2''-acetyl- β -glucopyranoside)-7-O- β -glucopyranoside:
 ($R_1 = \text{Glc}$ 2''-Ac; $R_3 = \text{Glc}$, $R_2 = R_5 = \text{H}$, $R_4 = \text{OH}$)
 (4a) quercetin 3-O- β -glucopyranoside-7-O- β -glucopyranoside undecaacetate:
 ($R_1 = R_3 = \text{Glc-Ac}$; $R_2 = R_5 = \text{Ac}$, $R_4 = \text{OAc}$)
 (5) kaempferol 3-O- β -glucopyranoside-7-O- α -rhamnopyranoside:
 ($R_1 = \text{Glc}$; $R_3 = \text{Rha}$; $R_2 = R_4 = R_5 = \text{H}$)
 (5a) kaempferol 3-O- β -glucopyranoside-7-O- α -rhamnopyranoside nonaacetate:
 ($R_1 = \text{Glc-Ac}$; $R_3 = \text{Rha-Ac}$, $R_2 = R_5 = \text{Ac}$, $R_4 = \text{H}$)
 (6) petiolaroside: $R_1 = \text{Glc}$; $R_3 = \text{Rha}$, $R_2 = R_5 = \text{H}$, $R_4 = \text{OH}$
 (6a) 2'' acetylpetiolaroside: $R_1 = \text{Glc}$ 2''-Ac; $R_3 = \text{Rha}$, $R_2 = R_5 = \text{H}$, $R_4 = \text{OH}$
 (6b) petiolaroside decaacetate: $R_1 = \text{Glc-Ac}$; $R_3 = \text{Rha-Ac}$; $R_2 = R_5 = \text{Ac}$, $R_4 = \text{OAc}$
 (7) quercetin 3-O-rhamnosylglucoside decaacetate:
 ($R_1 = 6\text{-RhaGlc-Ac}$; $R_2 = R_3 = R_5 = \text{Ac}$, $R_4 = \text{OAc}$)
 Glc = β -glucopyranosyl.
 Rha = α -rhamnopyranosyl.
 6-RhaGlc = α -rhamnopyranosyl-(1 \rightarrow 6)- β -glucopyranoside

3. Experimental

3.1. General experimental procedures

M.p.s are uncorrected and were taken on a Reichert Thermovar apparatus. IR spectra were measured on a Bruker TFS-55 spectrometer. Optical rotations were determined using

a PerkinElmer 2H polarimeter with a 1 dm cell. ^1H and ^{13}C NMR spectra were measured using a Bruker AMX-400 instrument. FAB MS and exact mass measurements were determined using a Micromass Autospec instrument at 70 eV. Column chromatograms used Sephadex LH-20 (Pharmacia ref. 17-0090-01), silica gel 60 (Merck 230–400 mesh), octadecyl-functionalized silica gel (Aldrich 377635-1006) and for analytical TLC, Merck Kieselgel 60 F_{254} . HPLC separations were performed on a JASCO Pu-980 series pumping system equipped with a JASCO UV-975 ultraviolet detector and with a Waters Kromasil Si 5 mm (10 mm \times 250 mm) column. A Macherey–Nagel VP 250/10 nuclear Sphinx RP, 5 μm column was used for HPLC-RP chromatography. Chromatograms were visualized under UV light at 255 and 366 nm and/or sprayed with oleum followed by heating. All solvents were distilled before use; the purity of all compounds was 99.0% as judged by high-performance liquid chromatography.

3.2. Plant material

Aerial parts of *Delphinium staphisagria* L. were collected in May 2006 in the Teno area, Tenerife, at an altitude of 120 m and identified by Prof. Pedro Perez de Paz, Botany Department, Faculty of Pharmacy, University of La Laguna, where a voucher specimen (TFC 46-325) has been deposited.

3.3. Extraction and isolation of the flavonoids

Chopped whole fresh plant (8 kg) was repeatedly extracted with 80% ethanol (12 l) at room temperature for 2 weeks. The extract was filtered and concentrated under reduced pressure until only H_2O remained. The remaining solution was extracted exhaustively with *n*-BuOH. The latter on removal of solvent afforded 35 g of residue. This was fractionated on a 50 cm \times 8 cm column packed with Sephadex LH-20 and eluted with hexane– CH_2Cl_2 –MeOH, 2:1:1, twenty-five 500 ml fractions being collected. Frs DS₁–DS₁₂ (13.8 g) contained mainly alkaloids and other components exhibiting no UV absorption while frs DS₁₃–DS₂₅ (9.5 g) contained primarily a mixture of glycosides and were subjected to low pressure chromatography on a RP C-18 7 cm \times 40 cm column using a linear gradient of 250 ml MeOH– H_2O mixtures ranging from 0 to 100% MeOH, 52 frs (DSA₁–DSA₅₂) being collected. Frs DSA_{15–21} (284 mg) were chromatographed over a polyamide column (35 cm \times 1 cm) and eluted with MeOH–EtOAc (3:2) to give in subfrs 14–20 after purification by crystallization from MeOH–EtOAc (2:1) 120 mg of paeonoside (**3**) identified by HRMS, ^1H and ^{13}C NMR spectrometry (Kamiya et al., 1997; Khetwal et al., 1988; Markham et al., 1978). Frs DSA_{23–24} (288 mg) were subjected to gel filtration on Sephadex LH-20 using CH_2Cl_2 –MeOH (1:1) as eluent, fifty 200 ml subfrs being collected. Subfrs 16–29 on crystallization from MeOH–EtOAc afforded 76 mg of 2''-acetylpaenoside (**3a**). Subfrs 36–42 on crystallization from MeOH–EtOAc afforded 22 mg of **4**; the material from the mother liquors on rechromatography over polyamide using EtOAc–MeOH 3:2 gave 29 mg of petiolaroside (**6**) identified by HRMS, ^1H and ^{13}C NMR spectrometry

(Akhov and Barl, 2003; Aly et al., 1975; Kerhoas et al., 2006; Shi et al., 1995). Frs DSA_{25–27} after cc over polyamide using MeOH–EtOAc (1:1) gave 150 mg of 2''-acetylpaeonoside (**3a**). Chromatography of frs DSA_{28–30} over a 35 cm × 1 cm polyamide column and elution with EtOAc–MeOH (3:2) afforded 24 mg of impure isoquercitrin (**2**) in subfrs 20–26 and in subfrs 6–12 18 mg of **5** after purification by RP HPLC chromatography (T_R 10.5 min, H₂O–MeOH–CH₃CN 3:1:1). The latter was identified by HRMS, ¹H and ¹³C NMR spectrometry and comparison with the literature (Özden et al., 1998). Acetylation of 18 mg of impure **2** in 0.5 ml of pyridine with 1 ml of Ac₂O overnight followed by the usual work-up and HPLC (hexane–EtOAc 2:3, flow rate 2 ml min⁻¹) furnished 8 mg of isoquercitrin octaacetate (**2a**), T_R 21 min, and 3 mg of rutin decaacetate (**7**), both identified by MS, ¹H and ¹³C NMR spectrometry (Demetzos et al., 1989; Jayasinghe et al., 2004).

Frs DSA_{35–37} on chromatography over a polyamide column (35 cm × 1 cm) and elution with EtOAc–MeOH (3:2) gave in subfrs 6–14 2''-acetylpetiolaroside (**6a**, 45 mg) and in subfrs 23–29 38 mg of astragaloside (**1**), the latter being identified by HRMS, ¹H and ¹³C NMR spectrometry (Kamiya et al., 1997; Lee et al., 1981; Markham et al., 1978). Frs DSA_{45–48} on recrystallization from H₂O–MeOH (3:1) furnished 85 mg of 2''-acetylastragaloside (**1a**)

3.3.1. Kaempferol 3-O-β-(2''-acetyl)-glucopyranoside (2''-acetylastragaloside) (**1a**)

Yellow powder, mp 152–153 °C (H₂O–MeOH 3:1), [α_D^{20}] –76.2 (MeOH, c = 0.04), IR $\gamma_{\max}^{\text{NaCl}}$ 3395 (OH), 1735, 1653, 1605, 1506, 1361, 1255, 1179, 1074, 670 cm⁻¹, UV λ_{\max} (MeOH) nm (log ϵ) 266 (4.0), 348 (3.9), FAB MS m/z : 513 (78) [M+Na]⁺, 471 (6) [M+Na–C₂H₂O]⁺, 439 (5), 406 (7), 366 (11), HR FAB MS m/z 513.0997 (calcd for C₂₃H₂₂O₁₂Na 513.1009), 471.0890 (calcd for C₂₁H₂₀O₁₁Na, 471.0903); ¹H NMR (400 MHz, pyridine-*d*₅) δ 6.72 (brs, 2H, H-6, H-8), 7.26 (d, J = 9 Hz, 2H, H-3', 5'), 8.47 (d, J = 9 Hz, 2H, H-2', 6'), 6.48 (d, J = 7.5 Hz, 3-O-Glc-1), 5.89 (dd, J = 9.5, 7.5 Hz, 3-O-Glc-2), 4.43 (t, J = 9.5 Hz, 3-O-Glc-3), 4.24 (dd, J = 10, 9.5 Hz, 3-O-Glc-4), 4.06 (ddd, J = 10, 5, 2.2 Hz, 3-O-Glc-5), 4.38 (dd, J = 11.8, 2.2 Hz, 3-O-Glc-6a), 4.22 (dd, J = 11.8, 5 Hz, 3-O-Glc-6b), 2.17 (s, 3p, Ac–Me); ¹³C NMR (100 MHz, pyridine-*d*₅) δ 157.6 (C-2), 134.9 (C-3), 178.9 (C-4), 163.4 (C-5), 100.3 (C-6), 166.4 (C-7), 95.1 (C-8), 157.9 (C-9), 105.2 (C-10), 122.4 (C-1'), 132.4 (C-2'), 116.7 (C-3'), 162.2 (C-4'), 116.7 (C-5'), 132.4 (C-6'), 101.2 (C-1-Glc), 76.3 (C-2-Glc), 76.5 (C-3-Glc), 72.1 (C-4-Glc), 79.6 (C-5-Glc), 62.8 (C-6-Glc) 171.0, 21.8 (Ac).

Acetylation of **1a** (16 mg) with 1.5 ml of Ac₂O and 1 ml of pyridine, stirring at r.t. overnight and work-up by pouring into cold H₂O, extraction with CHCl₃, drying (MeSO₄) and removal at solvent afforded 14 mg of crude product. Chromatography on silica coated preparative plates (hexane–EtOAc 1:1, twice) resulted in two bands the upper one of which yielded **1b** (4 mg), a new flavonol derivative. The lower zone was extracted with EtOAc to give after HPLC rechromatography (hexane–EtOAc 1:1, flow rate 1.9 ml min⁻¹),

3.6 mg of **1c**, another new flavonol derivative, T_R 20.5 min, and 8 mg of known **1d**, T_R 26 min), the latter being identified by HR FAB MS, ¹H and ¹³C NMR spectrometry (Lee et al., 1981; Matsuura and Inuma, 1978).

3.3.2. Kaempferol 3-O-β-(glucopyranoside)-7,4',2'',3'',4'',6''-hexaacetate (**1b**)

Yellow gum, [α_D^{20}] –84.8° (CHCl₃, c = 0.066); IR $\gamma_{\max}^{\text{NaCl}}$ 2922, 1754 (strong), 1653, 1609, 1370, 1212 (strong), 1068, 1039, 908, 756 cm⁻¹, UV λ_{\max} (CHCl₃) nm (log ϵ) 269 (3.84), 354 (3.56); FAB MS m/z 723 (39) [M+Na]⁺, 685 (10) [M–CH₃]⁺, 683 (7), [M+H–H₂O]⁺, 663 (19), 521 (16), 369 (17), 331 (37) HR FAB MS m/z 723.1547 (calcd for C₃₃H₃₂O₁₇Na 723.1537), 693.1420 (calcd for C₃₂H₃₀O₁₆Na, 693.1432), 685.1405 (calcd for C₃₂H₂₉O₁₇, 685.1405), 683.1644 (calcd for C₃₃H₃₁O₁₆, 683.1612); ¹H NMR (400 MHz, C₆D₆ at 65 °C) δ 6.71 (d, J = 1.8 Hz, H-6), 6.73 (d, J = 1.8 Hz, H-8), 7.26 (d, J = 8.9 Hz, H-3', 5'), 8.12 (d, J = 8.9 Hz, H-2', 6'), 5.88 (brd, J = 6.75 Hz, 3-O-Glc-1), 5.57 (brdd, J = 9.4, 6.7 Hz, 3-O-Glc-2), 5.56 (brt, J = 9.4 Hz, 3-O-Glc-3), 5.25 (brt, J = 9.4 Hz, 3-O-Glc-4), 3.36 (m, 3-O-Glc-5), 4.07 (dd, J = 12.5, 2.3 Hz), and 3.92 dd (12.5, 2.3 Hz, 3-O-Glc-6a,b), 2.00 (s, 3p), 1.88 (s, 3p), 1.84 (s, 3p), 1.83 (s, 3p), 1.76 (s, 3p), 1.75 (s, 3p)-Ac–Mes); ¹³C NMR (100 MHz, pyridine-*d*₅) δ 157.6 (C-2), 135.5 (C-3), 178.5 (C-4), 156.3 (C-5), 101.5 (C-6), 156.9 (C-7), 105.5 (C-8), 162.8 (C-9), 109.8 (C-10), 128.7 (C-1'), 131.3 (C-2'), 122.2 (C-3'), 153.8 (C-4'), 122.2 (C-5'), 131.3 (C-6'), 100.1 (C-1-Glc), 72.5 (C-2''-Glc), 73.5 (C-3''-Glc), 68.8 (C-4''-Glc), 72.8 (C-5''-Glc), 61.4 (C-6''-Glc); acetates 20.88, 20.82, 20.77, 20.54, 20.47, 20.43, 20, 170.1, 170.08, 169.8, 169.4, 168.2, 167.8.

3.3.3. Kaempferol 3-O-β (glucopyranoside)-5,4',2'',3'',4'',6''-hexaacetate (**1c**)

Colorless gum, [α_D^{20}] –33.3° (CHCl₃, c = 0.07); IR $\gamma_{\max}^{\text{NaCl}}$ 2918, 1753 (strong), 1631, 1369, 1211, 1070, 1038 cm⁻¹, UV λ_{\max} (CHCl₃) nm (log ϵ) 254 (3.97), 307 (3.98); FAB MS m/z 723 (15) [M+Na]⁺, 708 (1) [M+Na–CH₃]⁺, 682 (1), [M+Na+H–CH₂H₂O]⁺, 663 (15), 552 (17), 519 (27), 331 (37) HR FAB MS m/z 723.1543 (calcd for C₃₃H₃₂O₁₇Na 723.1537), 708.1287 (calcd for C₃₂H₂₉O₁₇Na, 708.1302), 682.1476 (calcd for C₃₁H₃₁O₁₆Na, 682.1510); ¹H NMR (400 MHz, C₆D₆) δ 6.37 (d, J = 2.1 Hz, H-6), 6.48 (d, J = 2.1 Hz, H-8), 8.17 (d, J = 8.9 Hz, H-2'), 7.24 (d, J = 8.9 Hz, H-3', 5'), 8.17 (d, J = 8.9 Hz, H-6'), 6.07 (d, J = 7.8, 3-O-Glc-1), 5.68 (dd, J = 9.6, 7.8 Hz, 3-O-Glc-2), 5.58 (t, J = 9.6 Hz, 3-O-Glc-3), 5.34 (dd, J = 10, 9.6 Hz, 3-O-Glc-4), 3.08 (ddd, J = 10, 3.5, 2.3 Hz, 3-O-Glc-5), 4.03 (dd, J = 12.5, 2.3 Hz, 3-O-Glc-6a), 3.92 (dd, J = 12.5, 2.3 Hz, 3-O-Glc-6b), 2.39 (s, 3p), 2.00 (s, 3p), 1.82 (s, 3p) 1.80 (s, 3p), 1.76 (s, 3p) 1.72 (s, 3p)-Ac–Mes); ¹³C NMR (100 MHz, C₆D₆) 155.3 (C-2), 136.8 (C-3), 172.8 (C-4), 158.3 (C-5), 101.6 (C-6), 161.2 (C-7), 109.3 (C-8), 151.8 (C-9), 112.1 (C-10), 127.7 (C-1'), 131.0 (C-2'), 121.9 (C-3'), 153.4 (C-4'), 121.9 (C-5'), 131.0 (C-6'), 99.6 (1''-Glc), 72.7 (2''-Glc), 73.6 (3''-Glc), 68.7 (4''-Glc), 72.5 (5''-Glc), 61.2 (6''-Glc); acetates δ 21.5, 20.09, 20.87, 20.84, 20.55, 20.45, 170.4, 170.1, 170.0, 169.7, 169.4, 168.5.

3.3.4. Kaempferol 3-O-β-(2''-acetylglucopyranoside)-7-O-β-glucopyranoside (2''-acetylpaenoside) (**3a**)

Yellow powder, mp 198–200 °C (MeOH–EtOAc), $[\alpha_D^{20}] -99.5^\circ$ (MeOH, $c = 0.18$); IR $\gamma_{\max}^{\text{NaCl}}$ 3354, 1727, 1657, 1598, 1488, 1207, 1179, 1070, cm^{-1} , UV λ_{\max} (MeOH) nm (log ϵ) 266 (3.9), 348 (3.9). FAB MS m/z 675 (24) $[\text{M}+\text{Na}]^+$, 642 (11), 637 (16) $[\text{M}-\text{CH}_3\text{O}]^+$, 505 (11), 449 (10); HR FAB MS m/z 675.1531 (calcd for $\text{C}_{29}\text{H}_{32}\text{O}_{17}\text{Na}$ 675.1537); ^1H NMR (pyridine- d_5) δ 6.80 (d, $J = 2.5$ Hz, H-6), 7.00 (d, $J = 2.5$ Hz, H-8), 7.25 (d, $J = 9$ Hz, H-3',5'), 8.44 (d, $J = 9$ Hz, H-2',6') 6.47 (d, $J = 8.2$ Hz, 3-O-Glc-1), 5.88 (dd, $J = 9.5, 8.2$ Hz, 3-O-Glc-2), 4.43 (t, $J = 9.5$ Hz, 3-O-Glc-3), 4.22 (t, $J = 9.5$ Hz, 3-O-Glc-4), 4.06 (ddd, $J = 9.5, 5.5, 2.2$ Hz, 3-O-Glc-5), 4.41 m and 4.20 m (3-O-Glc-6a,b), 5.84 (d, $J = 7.5$ Hz, 7-O-Glc-1), 4.37 (m, 7-O-Glc-2), 4.43 (m, 7-O-Glc-3) 4.36 (m, 7-O-Glc-4), 4.21 (m, 7-O-Glc-5), 4.61 (dd, $J = 12, 2$ Hz, 7-O-Glc-6a), 4.42 (m, 7-O-Glc-6b), 2.16 (s, 3p, Ac–Me); ^{13}C NMR (100 MHz, pyridine- d_5) δ 158.1 (C-2), 135.1 (C-3), 179.0 (C-4), 162.7 (C-5), 100.9 (C-6), 164.4 (C-7), 95.5 (C-8), 157.3 (C-9), 107.3 (C-10), 122.1 (C-1'), 132.4 (C-2',6'), 116.7 (C-3',5'), 162.7 (C-4'), 101.0 (3-Glc, C-1'), 72.3 (3-Glc, C-2'), 76.4 (3-Glc, C-3'), 72.1 (3-Glc, C-4'), 79.8 (3-Glc, C-5'), 63.0 (3-Glc, C-6'), 102.2 (7-Glc, C-1''), 75.3 (7-Glc, C-2''), 78.9 (7-Glc, C-3''), 71.5 (7-Glc, C-4''), 79.7 (7-Glc, C-5''), 62.8 (7-Glc, C-6''), 171.1, 21.9 (Ac). Peracetylation of **3a** furnished the known paenoside decaacetate **3b** (Nikolov et al., 1986; Akhov and Barl, 2003).

3.3.5. Quercetin 3-O-β-(2''-acetylglucopyranoside)-7-O-β-glucopyranoside (**4**)

Yellow powder, mp 168–170 °C (MeOH–EtOAc), $[\alpha_D^{20}] -96^\circ$ (MeOH, $c = 0.1$); IR $\gamma_{\max}^{\text{NaCl}}$ 3360 (OH), 1734, 1652, 1600, 1558, 1204, 1070, cm^{-1} , UV λ_{\max} (MeOH) nm (log ϵ) 259 (3.95), 356 (3.96). FAB MS m/z 691 (45) $[\text{M}+\text{Na}]^+$, 669 (20), 649 (20) $[\text{M}+\text{C}_2\text{H}_2\text{O}]^+$, 346 (65), 313 (100); HR FAB MS m/z 691.1459 (calcd for $\text{C}_{29}\text{H}_{32}\text{O}_{18}\text{Na}$ 691.1486), 669.1671 (calcd for $\text{C}_{29}\text{H}_{33}\text{O}_{18}$, 669.1667), 668.1588 (calcd for $\text{C}_{29}\text{H}_{32}\text{O}_{18}$, 668.1589). ^1H NMR (pyridine- d_5) δ 6.79 (d, $J = 2$ Hz, H-6), 6.89 (d, $J = 2$ Hz, H-8), 8.33 (d, $J = 2.2$ Hz, H-2'), 7.34 (d, $J = 8.5$ Hz, H-5') 8.13 (dd, $J = 8.5, 2.2$ Hz, H-6'), 6.36 (d, $J = 8$ Hz, 3-O-Glc-1), 5.85 (dd, $J = 9.5, 3$ -O-Glc-2), 4.41 (t, $J = 9.5$ Hz, 3-O-Glc-3), 4.15 (dd, $J = 10, 9.5$ Hz, 3-O-Glc-4), 4.06 (ddd, $J = 10, 5.5, 2.2$ Hz, 3-O-Glc-5), 4.41 (dd, $J = 12, 2.2$ Hz, 3-O-Glc-6a), 4.21 (dd, $J = 12, 5.5$ Hz, 3-O-Glc-6b), 5.80 (d, $J = 7.5$ Hz, 7-O-Glc-1), 4.35 (m, 7-O-Glc-2), 4.43 (m, 7-O-Glc-3), 4.36 (m, 7-O-Glc-4), 4.21 (m, 7-O-Glc-5), 4.58 (dd, $J = 4.5, 2.5$ Hz, 7-O-Glc-6a), 4.48 (m, 7-O-Glc-6b), 2.15 (s, 3p, Ac); ^{13}C NMR (100 MHz, pyridine- d_6) δ 158.4 (C-2), 135.4 (C-3), 178.9 (C-4), 162.7 (C-5), 100.7 (C-6), 164.3 (C-7), 95.4 (C-8), 157.2 (C-9), 107.3 (C-10), 122.6 (C-1'), 118.1 (C-2'), 147.3 (C-3'), 151.4 (C-4'), 116.8 (C-5'), 123.4 (C-6'), 101.4 (3-Glc, C-1'), 76.2 (3-Glc, C-2'), 78.9 (3-Glc, C-3'), 72.0 (3-Glc, C-4'), 79.6 (3-Glc, C-5'), 62.8 (3-Glc, C-6'), 102.1 (7-Glc, C-1''), 75.2 (7-Glc, C-2''), 76.4 (7-Glc, C-3''), 71.5 (7-Glc, C-4''), 79.7 (7-Glc, C-5''), 62.8 (7-Glc, C-6''), 170.9, 21.7 (Ac). Peracetylation of monoacetate **4** furnished the known quercetin 3,7-diglycoside undecaacetate **4a** (Kato et al., 1990).

3.3.6. Quercetin-3-O-β-(2''-acetylglucopyranoside)-7-O-α-rhamnopyranoside (2''-acetyl-petiolaroside) (**6a**)

Yellow powder, mp 250–252 °C (MeOH–EtOAc), $[\alpha_D^{20}] -113.6^\circ$ (MeOH, $c = 0.04$); IR $\gamma_{\max}^{\text{NaCl}}$ 3410 (OH), 1724, 1657, 1595, 1481, 1300, 1206, 1075 cm^{-1} , UV λ_{\max} (MeOH) nm (log ϵ) 257 (4.11), 356 (4.0). FAB MS m/z 675 (45) $[\text{M}+\text{Na}]^+$, 652 (6) $[\text{M}]^+$, 638 (32), 582 (26), 446 (46), 346 (72) HR FAB MS m/z 675.1550 (calcd for $\text{C}_{29}\text{H}_{32}\text{O}_{17}\text{Na}$ 675.1537) $[\text{M}+\text{Na}]^+$, 652.1647 (calcd for $\text{C}_{29}\text{H}_{32}\text{O}_{17}$, 652.1640) $[\text{M}]^+$. ^1H NMR (400 MHz, pyridine- d_5) δ 6.74 (d, $J = 2$ Hz, H-6), 6.80 (d, $J = 2$ Hz, H-8) 8.28 (d, $J = 2.2$ Hz, H-2'), 7.40 (d, $J = 8.5$ Hz, H-5'), 8.22 (dd, $J = 8.5, 2$ Hz, H-6'), 6.39 (d, $J = 8$ Hz, 3-Glc-1), 5.87 (dd, $J = 9.3, 8$ Hz, 3-Glc-2), 4.41 (t, $J = 9.3$ Hz, 3-Glc-3) 4.19 (t, $J = 9.3$ Hz, 3-Glc-4), 4.07 (ddd, $J = 9.3, 5.3, 2.3$ Hz, 3-Glc-5), 4.40 (dd, $J = 12.2, 2.3$ Hz, 3-Glc-6a), 4.23 (dd, $J = 12.2, 5.3$ Hz, 3-Glc-6b), 6.21 (brs, 7-Rha-1), 4.72 (brs, 7-Rha-2), 4.67 (brd, $J = 9.3$ Hz, 7-Rha-3), 4.41 (t, $J = 9.2, 7$ -Rha-4), 4.27 (dq, $J = 9.2, 6$ Hz, 7-Rha-5), 1.66 (d, 6, 3p, 7-Rha-6), 2.16 (s, 3p, Ac–Me), ^{13}C NMR (100 MHz, pyridine- d_5) δ 158.3 (C-2), 135.5 (C-3), 179.0 (C-4), 162.8 (C-5), 100.8 (C-6), 163.15 (C-7), 95.1 (C-8), 157.3 (C-9), 107.3 (C-10), 122.5 (C-1'), 117.9 (C-2'), 147.5 (C-3'), 151.6 (C-4'), 116.9 (C-5'), 123.7 (C-6'), 101.5 (3-Glc, C-1'), 76.2 (3-Glc, C-2'), 76.5 (3-Glc, C-3'), 72.0 (3-Glc, C-4'), 79.6 (3-Glc, C-5'), 62.9 (3-Glc, C-6'), 100.4 (7-Rha, C-1), 72.1 (7-Rha, C-2), 72.9 (7-Rha, C-3), 74.1 (7-Rha, C-4), 71.9 (7-Rha, C-5), 19.3 (7-Rha, C-6), 21.7, 171.10 (Ac). Peracetylation of **6a** afforded the known petiolaroside decaacetate **6b** (Díaz et al., 2005).

References

- Akhov, L., Barl, B., 2003. Isolation of quercetin glycosides from leaves of sea buckthorn (*Hippophae rhamnoides* ssp *mongolica*). Acta Horti. 626, 384–395.
- Aly, H.F., Geiger, H., Schuecker, U., Waldrum, H., Vander Velde, G., Mabry, T.J., 1975. Flavonol glycosides from *Equisetum silvaticum*. Phytochemistry 14, 1613–1615.
- Arazashvili, A.I., Moniava, I.T., Kemertelidze, E.P., 1973. Flavonoids of *Delphinium flexuosum* and *Delphinium elisabethae*. Khim. Prir. Soedin. 9, 556–557.
- Arazashvili, A.I., Moniava, I.T., Kemertelidze, E.P., 1974. Flavonoids from some species of *Delphinium*. Khim. Prir. Soedin. 10, 251.
- Demetzos, C., Mitaku, S., Hotellier, F., Harvala, A., 1989. Polyphenolic glycosides from *Cistus creticus* leaves. Ann. Pharm. France 47, 314–318 Chem. Abstr. 113, 37728 (1990).
- Díaz, J.G., Ruiz, J.G., De La Fuente, G., 2000. Alkaloids from *Delphinium staphisagria* J. Nat. Prod. 63, 1136–1139.
- Díaz, J.G., Ruiz, J.G., Díaz, B.R., Sazatornil, J.A.G., Herz, W., 2005. Flavonol 3,7-glycosides and dihydrophenethyl glycosides from *Aconitum napellus* ssp. *lusitanicum*. Biochem. Syst. Ecol. 33, 201–205.
- Jayasinghe, U.L.B., Balasooriya, B.A.I.S., Bandara, A.G.D., Fujimoto, Y., 2004. Glycosides from *Grewia damine* and *Filicium decipiens*. Nat. Prod. Res. 18, 499–502 Chem. Abstr. 142, 352103 (2005).
- Kamiya, K., Yoshioka, K., Saiki, Y., Ikuta, A., Satake, T., 1997. Triterpenoids and flavonoids from *Paeonia lactiflora*. Phytochemistry 44, 141–144.
- Kato, T., Yamane, F., Morita, Y., 1990. Flavonol glycosides and other constituents from the leaves of *Ampelopsis brevipedunculata* Trutv. Shoyakugaku Zasshi. 44, 138–142 Chem. Abstr. 114:58890 (1991).
- Kerhoas, L., Aouak, D., Cingoz, A., Routaboul, J.-M., Lepiniac, L., Einhorn, J., Birlirakis, N., 2006. Structural characterization of the major flavone glycosides from *Arabidopsis thaliana* seeds. J. Agric. Food Chem. 54, 6603–6612.

- Khetwal, K.S., Manral, K., Verma, D.L., 1988. Flavonoids from the roots of *Sedum cressipes*. *Planta Med.* 54, 89–90.
- Lee, K.H., Tagahara, K., Suzuki, H., Wu, R.Y., Haruna, M., Hall, I.H., Huang, H.C., Ito, K., Iida, T., Lai, J.S., 1981. Antitumor agents 49. Tricin, kaempferol 3-O- β -D-glucopyranoside and (+)-nortrachelogenin, antileukemic principles from *Wikstroemia indica*. *J. Nat. Prod.* 44, 530–535.
- Lomadze, I.A., Dzhagamadze, N.N., Moniava, I.I., Bostoganashvili, V.S., 1976. Quantitative determination of some flavonoids in plants. *Soobshcheniya Akad. Nauk. Gruzinskoi SSR* 84, 369–371 *Chem. Abstr.* 86, 86154 (1977).
- Markham, K.R., Ternai, B., Stanley, R., Geiger, H., Mabry, T.J., 1978. Carbon-13 NMR studies of flavonoids. III. Naturally occurring flavonoid glycosides and their acylated derivatives. *Tetrahedron* 34, 1389–1397.
- Matsuura, S., Iinuma, M., 1978. Studies on the constituents of useful plants VI. Constituents of the calyx of *Diospyros kaki* and carbon-13 nuclear magnetic resonance spectra of flavonol glycosides. *Chem. Pharm. Bull.* 26, 1936–1941.
- Nikolov, N., Seligmann, O., Wagner, H., 1986. New flavonol glycosides from *Mespilus germanica* L. In: *Studies in Organic Chemistry*, Amsterdam, pp. 251–260.
- Özden, S., Dürüst, N., Toki, K., Saito, N., Honda, T., 1998. Acylated kaempferol glycosides from flowers of *Delphinium formosum*. *Phytochemistry* 49, 241–245.
- Shi, Q., Chen, K., Li, L., Chang, J.J., Autry, C., Kuzuka, M., Konoshima, T., Estes, J.R., Lin, C.M., Hamil, E., McPhail, A.T., McPhail, D.M., Lee, K.-H., 1995. Antitumor agents 154. Cytotoxic and antimitotic flavonols from *Polanisia dodecandra*. *J. Nat. Prod.* 58, 475–482.
- Strzelecka, H., Dobrowolska, B., 1976. Flavonoid compounds in *Delphinium grandiflorum*. *Acta Pol. Pharm.* 33, 135 *Chem. Abstr.* 85, 189225 (1976).
- Warnock, M.J., Liu, Y.-L., Mabry, T.J., 1983. Acylated flavonols from *Delphinium carolinianus*. *Phytochemistry* 22, 1834–1835.
- Yoshimitsu, H., Nishida, M., Hashimoto, F., Tanaka, M., Sakata, Y., Okawa, M., Nohara, T., 2007. Chromone and flavonol glycosides for *Delphinium hybridum* cv. “Belladonna Casablanca”. *J. Nat. Med.* 61, 334–338.
- Yunusova, M.S., Nigmanova, A., 1976. Flavonoids of *Delphinium semibarbatum* growing in Uzbekistan. *Vopr. Farmacol. Farmatsii* 75–76 *Chem. Abstr.* 88, 86056 (1978).